egfr antisense dna
Nucleic acidexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 1999 (NCT00009841)
Timeline
1990s
- Jan 1, 1999
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
EGFR inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- egfr antisense dna
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01592721 | Phase 1/Phase 2 (Phase 2) | Apr 1, 2013 | University of Pittsburgh, University of Texas, San Antonio |
| NCT00903461 | Phase 1 | Apr 1, 2012 | National Cancer Institute (NCI), University of Pittsburgh |
| NCT00009841 | Phase 1 | Mar 1, 1999 | National Cancer Institute (NCI), University of Pittsburgh |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of Pittsburgh | Academic/Hospital | 3 | 2 | 2 | 1999 |
| National Cancer Institute (NCI) | Government | 2 | 0 | 1 | 1999 |
| University of Texas, San Antonio | Academic/Hospital | 1 | 1 | 1 | 2013 |
3 organizations
Page 1 / 1